TransMedics Director Sells Shares for Approximately $722,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: NASDAQ.COM
- Share Sale Details: TransMedics Group director Thomas J. Gunderson sold 9,624 shares of common stock on June 15, 2026, for a total transaction value of approximately $722,000, reflecting routine portfolio management following the exercise of vested stock options.
- Transaction Context: The sale was executed immediately after exercising stock options to cover exercise costs and tax obligations, indicating proactive portfolio management amid a roughly 45% decline in share price over the past year.
- Financial Performance Highlights: TransMedics generated record revenue of $173.9 million in Q1, up 21% year-over-year, while reiterating full-year revenue guidance of $727 million to $757 million, representing expected growth of 20% to 25%, despite missing market expectations.
- Future Growth Potential: Although profitability has compressed, TransMedics reported a net income of $7.3 million and ended the quarter with $461.7 million in cash, with the CEO emphasizing a focus on executing growth strategies to expand access to life-saving transplants globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMDX
Wall Street analysts forecast TMDX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 71.230
Low
115.00
Averages
147.80
High
170.00
Current: 71.230
Low
115.00
Averages
147.80
High
170.00
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TransMedics Invests in PAD Aviation to Enhance Organ Transport
- Strategic Investment: TransMedics' investment in Germany-based PAD Aviation marks a critical step in establishing a dedicated organ transplantation air logistics network in Europe, which is expected to significantly enhance organ transport efficiency and support transplant activities across the EU.
- Technology Replication: By replicating the U.S. OCS NOP model, TransMedics aims to expand the adoption of OCS perfusion technology, which is anticipated to increase the utilization of donor organs in Europe, thereby saving more patients' lives.
- PAD Aviation Advantages: Since its founding in 2006, PAD Aviation has leveraged its modern fleet and 24/7 operational hub to rapidly respond to time-critical organ transport missions, enhancing TransMedics' competitive edge in the organ transport sector.
- Market Potential: This investment not only strengthens TransMedics' positioning in the European market but also provides strategic support for future growth, expected to drive further development and application of organ transplantation technologies.
See More
TransMedics Invests in PAD Aviation to Enhance Organ Transport Network
- Strategic Investment: TransMedics has completed its strategic investment in Germany-based PAD Aviation, aiming to establish a dedicated European organ transplantation air logistics network by replicating the U.S. OCS NOP model, thereby enhancing organ utilization and saving more patients.
- Operational Integration: PAD Aviation operates a modern fleet, including nine Embraer Phenom 300 aircraft, with 24/7 operational capabilities that can rapidly respond to time-critical organ transport needs, which is expected to significantly enhance TransMedics' service capabilities in organ logistics.
- Market Opportunity: This investment not only strengthens TransMedics' competitive position in the European market but also provides the company with opportunities to expand its influence in the organ transplantation sector, likely driving growth in transplant activities.
- Leadership Support: TransMedics CEO Waleed Hassanein stated that the partnership with PAD Aviation will create significant opportunities to increase the utilization of precious donor organs, further solidifying the company's leadership in organ transplantation technology.
See More
TransMedics: Revolutionizing the Organ Transplant Market
- Organ Transport Innovation: TransMedics' Organ Care System (OCS) significantly extends the viability of donor organs by keeping them warm and perfused with oxygenated blood, allowing surgeons to assess organ quality in real time, fundamentally changing how transplant medicine operates.
- Massive Market Potential: With over 90,000 people waiting for kidney transplants in the U.S., TransMedics is actively developing a kidney OCS program, which, if successful, could dramatically expand its addressable market and solidify its leadership in organ transplantation.
- European Expansion Strategy: TransMedics recently announced a strategic investment in Germany's PAD Aviation to replicate the U.S. National OCS Program model in Europe, while collaborating with Mercedes-Benz for ground transportation in Italy, showcasing its ambition for international growth.
- Financial Challenges and Growth: Despite a significant rise in operating expenses leading to slight gross margin compression in the latest quarter, the company still achieved a 21% year-over-year revenue growth, indicating strong market demand and growth potential amid its expansion efforts.
See More
TransMedics: Disrupting the Organ Transplant Market
- Significant Market Potential: With over 90,000 Americans waiting for kidney transplants, TransMedics' successful OCS Kidney program could dramatically expand the company's addressable market, enhancing its competitive edge in organ transplantation.
- Unique Logistics Network: TransMedics has established the National OCS Program, featuring a fleet of 22 fixed-wing aircraft and specialized clinical teams, creating a vertically integrated logistics system that ensures organ viability during transport, thereby improving transplant success rates.
- European Expansion Strategy: The company recently invested in Germany's PAD Aviation to replicate the U.S. NOP model across Europe, and it has also partnered with Mercedes-Benz in Italy for ground transportation, further strengthening its international market presence.
- Financial Challenges and Growth: Despite a significant rise in operating expenses in the latest quarter leading to slight gross margin compression, the company still achieved a 21% year-over-year revenue growth, indicating strong market demand and potential during its expansion phase.
See More
Three Stocks Worth Watching Amid Market Pullback
- SoFi Technologies Performance: SoFi's stock has declined 34% this year, yet its total revenue surged 43% year-over-year to $1.1 billion, indicating strong financial performance that may attract more investor interest despite the short-seller report impact.
- Robinhood Market Dynamics: Robinhood's revenue increased by 15% year-over-year to $1.07 billion, although its cryptocurrency revenue fell 47% to $134 million; however, the 57% growth in Gold premium subscriptions suggests potential for diversified revenue streams.
- TransMedics Group Financial Status: TransMedics reported a 21% year-over-year revenue increase to $173.9 million, despite a drop in operating margin to 7.6%, as the company invests heavily in international expansion and R&D, which is expected to drive future growth.
- Market Outlook Analysis: These three companies possess unique competitive advantages in their respective fields, and despite facing short-term challenges, their long-term growth potential and market positioning make them worthy investment candidates.
See More
Three Stocks Worth Investing In After Market Pullback
- SoFi Financial Performance: SoFi Technologies reported a 43% year-over-year revenue increase to $1.1 billion, despite a 34% stock price drop due to a short-seller report; however, its adjusted EPS doubled to $0.12, indicating strong performance in the fintech sector and potential to attract more young users in the future.
- Robinhood Revenue Challenges: Robinhood's Q1 revenue grew 15% year-over-year to $1.07 billion, but overall growth was hampered by a 47% decline in cryptocurrency trading revenue to $134 million; however, its Gold subscription service revenue surged 57%, showcasing the potential for diversified income streams.
- TransMedics Expansion Strategy: TransMedics Group's revenue increased by 21% year-over-year to $173.9 million, although its operating margin fell to 7.6%, the company is actively expanding internationally and investing in R&D to promote its Organ Care System for more organs, indicating significant future growth potential.
- Market Outlook Analysis: Despite facing short-term challenges, the long-term outlook for these three companies remains optimistic, as SoFi and Robinhood's business models cater to younger consumer demands, while TransMedics' innovative technology holds a crucial position in the healthcare market, making them attractive options for investors looking to capitalize on current market dips.
See More
TransMedics Invests in PAD Aviation to Enhance Organ Transport
- Strategic Investment: TransMedics' investment in Germany-based PAD Aviation marks a critical step in establishing a dedicated organ transplantation air logistics network in Europe, which is expected to significantly enhance organ transport efficiency and support transplant activities across the EU.
- Technology Replication: By replicating the U.S. OCS NOP model, TransMedics aims to expand the adoption of OCS perfusion technology, which is anticipated to increase the utilization of donor organs in Europe, thereby saving more patients' lives.
- PAD Aviation Advantages: Since its founding in 2006, PAD Aviation has leveraged its modern fleet and 24/7 operational hub to rapidly respond to time-critical organ transport missions, enhancing TransMedics' competitive edge in the organ transport sector.
- Market Potential: This investment not only strengthens TransMedics' positioning in the European market but also provides strategic support for future growth, expected to drive further development and application of organ transplantation technologies.
See More
TransMedics Invests in PAD Aviation to Enhance Organ Transport Network
- Strategic Investment: TransMedics has completed its strategic investment in Germany-based PAD Aviation, aiming to establish a dedicated European organ transplantation air logistics network by replicating the U.S. OCS NOP model, thereby enhancing organ utilization and saving more patients.
- Operational Integration: PAD Aviation operates a modern fleet, including nine Embraer Phenom 300 aircraft, with 24/7 operational capabilities that can rapidly respond to time-critical organ transport needs, which is expected to significantly enhance TransMedics' service capabilities in organ logistics.
- Market Opportunity: This investment not only strengthens TransMedics' competitive position in the European market but also provides the company with opportunities to expand its influence in the organ transplantation sector, likely driving growth in transplant activities.
- Leadership Support: TransMedics CEO Waleed Hassanein stated that the partnership with PAD Aviation will create significant opportunities to increase the utilization of precious donor organs, further solidifying the company's leadership in organ transplantation technology.
See More
TransMedics: Revolutionizing the Organ Transplant Market
- Organ Transport Innovation: TransMedics' Organ Care System (OCS) significantly extends the viability of donor organs by keeping them warm and perfused with oxygenated blood, allowing surgeons to assess organ quality in real time, fundamentally changing how transplant medicine operates.
- Massive Market Potential: With over 90,000 people waiting for kidney transplants in the U.S., TransMedics is actively developing a kidney OCS program, which, if successful, could dramatically expand its addressable market and solidify its leadership in organ transplantation.
- European Expansion Strategy: TransMedics recently announced a strategic investment in Germany's PAD Aviation to replicate the U.S. National OCS Program model in Europe, while collaborating with Mercedes-Benz for ground transportation in Italy, showcasing its ambition for international growth.
- Financial Challenges and Growth: Despite a significant rise in operating expenses leading to slight gross margin compression in the latest quarter, the company still achieved a 21% year-over-year revenue growth, indicating strong market demand and growth potential amid its expansion efforts.
See More
TransMedics: Disrupting the Organ Transplant Market
- Significant Market Potential: With over 90,000 Americans waiting for kidney transplants, TransMedics' successful OCS Kidney program could dramatically expand the company's addressable market, enhancing its competitive edge in organ transplantation.
- Unique Logistics Network: TransMedics has established the National OCS Program, featuring a fleet of 22 fixed-wing aircraft and specialized clinical teams, creating a vertically integrated logistics system that ensures organ viability during transport, thereby improving transplant success rates.
- European Expansion Strategy: The company recently invested in Germany's PAD Aviation to replicate the U.S. NOP model across Europe, and it has also partnered with Mercedes-Benz in Italy for ground transportation, further strengthening its international market presence.
- Financial Challenges and Growth: Despite a significant rise in operating expenses in the latest quarter leading to slight gross margin compression, the company still achieved a 21% year-over-year revenue growth, indicating strong market demand and potential during its expansion phase.
See More
Three Stocks Worth Watching Amid Market Pullback
- SoFi Technologies Performance: SoFi's stock has declined 34% this year, yet its total revenue surged 43% year-over-year to $1.1 billion, indicating strong financial performance that may attract more investor interest despite the short-seller report impact.
- Robinhood Market Dynamics: Robinhood's revenue increased by 15% year-over-year to $1.07 billion, although its cryptocurrency revenue fell 47% to $134 million; however, the 57% growth in Gold premium subscriptions suggests potential for diversified revenue streams.
- TransMedics Group Financial Status: TransMedics reported a 21% year-over-year revenue increase to $173.9 million, despite a drop in operating margin to 7.6%, as the company invests heavily in international expansion and R&D, which is expected to drive future growth.
- Market Outlook Analysis: These three companies possess unique competitive advantages in their respective fields, and despite facing short-term challenges, their long-term growth potential and market positioning make them worthy investment candidates.
See More
Three Stocks Worth Investing In After Market Pullback
- SoFi Financial Performance: SoFi Technologies reported a 43% year-over-year revenue increase to $1.1 billion, despite a 34% stock price drop due to a short-seller report; however, its adjusted EPS doubled to $0.12, indicating strong performance in the fintech sector and potential to attract more young users in the future.
- Robinhood Revenue Challenges: Robinhood's Q1 revenue grew 15% year-over-year to $1.07 billion, but overall growth was hampered by a 47% decline in cryptocurrency trading revenue to $134 million; however, its Gold subscription service revenue surged 57%, showcasing the potential for diversified income streams.
- TransMedics Expansion Strategy: TransMedics Group's revenue increased by 21% year-over-year to $173.9 million, although its operating margin fell to 7.6%, the company is actively expanding internationally and investing in R&D to promote its Organ Care System for more organs, indicating significant future growth potential.
- Market Outlook Analysis: Despite facing short-term challenges, the long-term outlook for these three companies remains optimistic, as SoFi and Robinhood's business models cater to younger consumer demands, while TransMedics' innovative technology holds a crucial position in the healthcare market, making them attractive options for investors looking to capitalize on current market dips.
See More
